Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Tecentriq, Hemlibra Get Off with a Bang, Clear 2018 Targets Already: Chugai
Chugai Pharmaceutical has seen bullish revenues from two major product launches this year - Tecentriq (atezolizumab) and Hemlibra (emicizumab). After achieving their 2018 targets just months following their debuts, both drugs are on tap for further growth with more lucrative…
To read the full story
Related Article
- Chugai Renews Record Earnings in 2018 on New Drugs, Exports
February 1, 2019
BUSINESS
- Fycompa Generics Approved despite Extended Patent, Hydrate Switch in Play?
February 17, 2026
- Espha Snags Bilanoa AG in Final Pre-Rule Approval Window
February 17, 2026
- Rakuten to Launch Japan PI of RM-0256 Photoimmunotherapy in April-June
February 17, 2026
- Kidswell, Treehill to Form US Firm for Cell Therapy Development
February 17, 2026
- Ono’s Velexbru Accepted for FDA Review in PCNSL
February 17, 2026
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…